University Hospital Zurich, Dermatology, Gloriastr. 31, 8091 Zurich, Switzerland.
Curr Opin Virol. 2013 Jun;3(3):357-62. doi: 10.1016/j.coviro.2013.05.004. Epub 2013 Jun 1.
Most antiviral vaccines are based on viral particles, which are efficient inducers of B cell responses. In addition to their ability to replicate, several features associated with the structure and content of the viral particles are responsible for this high immunogenicity. First, viral particles usually have dimensions between 20 and 200 nm, a size optimal for drainage to lymph nodes and direct interaction with B cells. Second, the surface of most viral particles is highly repetitive, causing efficient cross-linking of B cell receptors, an early and key step of B cell activation. In addition, such repetitive structures bind natural antibodies and fix complement, further enhancing B cell activation as well as transport to and deposition on follicular dendritic cells. Third, viral particles carry ligands for toll-like receptor 7/8 or 9 which activate B cells directly for isotype switching as well as dendritic cells for T cell priming. In this review, we will highlight recent insights in these mechanisms and discuss their impact on antiviral antibody responses.
大多数抗病毒疫苗基于病毒颗粒,这些颗粒是诱导 B 细胞反应的有效诱导剂。除了能够复制之外,与病毒颗粒的结构和内容相关的几个特征也导致了其高度的免疫原性。首先,病毒颗粒的尺寸通常在 20 到 200nm 之间,这是引流到淋巴结并与 B 细胞直接相互作用的最佳尺寸。其次,大多数病毒颗粒的表面高度重复,导致 B 细胞受体的有效交联,这是 B 细胞激活的早期和关键步骤。此外,这种重复结构结合了天然抗体并固定补体,进一步增强了 B 细胞的激活以及运输到滤泡树突状细胞并沉积在其上。第三,病毒颗粒携带 Toll 样受体 7/8 或 9 的配体,直接激活 B 细胞进行同种型转换以及树突状细胞进行 T 细胞启动。在这篇综述中,我们将重点介绍这些机制的最新见解,并讨论它们对抗病毒抗体反应的影响。